This document is a patent publication notice from the EPO announcing the grant of patent EP3213768A1. The patent covers methods of treating metastatic cancer using a combination of low-dose immune checkpoint inhibitors and high-dose IL-2 cytokine therapy. The applicants and inventors are Ralf Kleef and Tibor Bakács. The patent is classified under pharmaceutical compositions (A61K) and immunotherapy antibodies (C07K).

Pharmaceutical companies and researchers developing cancer immunotherapies should review the patent claims to assess potential licensing needs or freedom-to-operate implications in European markets. The patent designation covers 31 EPO member states including major markets such as Germany, France, the United Kingdom, Italy, and Spain. Patent protection typically extends for 20 years from the filing date.